ArticlePloS one2018

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.

Åsa Ericsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.